MicroCME: How Best To Use FeNo
Price: FREE to members; $20 non-members
Length: 30 minutes
This microlearning, presented by Dr. Njira Lugogo, explains the role of biomarkers in identifying asthma phenotypes; describes the role of FeNO in asthma phenotypic characterization; discusses clinical implications of FeNO in asthma outcomes; and reviews the role of FeNO in predicting treatment responses across the asthma spectrum.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Primary Care Providers
Fellows-in-Training
Learning Objectives
By participating in this course, learners should be able to:
1. Explain the role of biomarkers in identifying asthma phenotypes
2. Describe the role of fractional exhaled nitric oxide (FeNO) in asthma phenotypic characterization
3. Discuss clinical implications of FeNO in asthma outcomes (lung function and exacerbations)
4. Review the role of FeNO in predicting treatment responses across the asthma spectrum
Planners and Reviewers
Brianne Nicole Navetta-Modrov, MD, FACAAI
Nothing to Disclose
Deepa Patadia, MD
Nothing to Disclose
Deepti Vellaichamy Manian, MD
Nothing to Disclose
Farah Nawaz Khan, MD, FACAAI
Doximity: stocks/stock options
Joel S. Klein, MD, FACAAI
Nothing to Disclose
Karen M. Anstey, MD
Nothing to Disclose
Tammy Peng, MD
Nothing to Disclose
Mary Brandt Hudelson, MD, FACAAI
Nothing to Disclose
Mechelle Miller Vazquez, MD
Nothing to Disclose
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance